Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 1/2016

22.01.2016 | Case Report

A Case Presenting with Splenic Infarct Diagnosed as Primary Bone Marrow CD5 Positive DLBCL: A Clinicopathological Correlation

verfasst von: Anupriya Bansal, Suchi Mittal, Jasmita Dass, Nitin Gupta, P. K. Agarwal, Jyoti Kotwal

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Sonderheft 1/2016

Einloggen, um Zugang zu erhalten

Abstract

De novo CD5+ Diffuse large B cell lymphoma (DLBCL) is a rare and aggressive subtype of DLBCL. It is a distinct clinicopathologic entity with complex molecular profile and poor prognosis. A 59 year old female presented with pyrexia of unknown origin since 1 month. On examination, there was severe pallor, hepatosplenomegaly and no palpable lymphadenopathy. Complete blood count revealed bicytopenia with normal total leucocyte count. Liver and renal function tests were normal. Ultrasonography abdomen revealed splenic enlargement with two focal lesions attributed to either splenic abscess or infarcts. Patient was being managed as splenic infarct but continued to have bicytopenia. Further investigation showed elevated serum ferritin, triglycerides and LDH. With a clinical suspicion of infection and haemophagocytic lymphohistiocytosis bone marrow aspiration (BMA) and biopsy (BMBx) was done. BMA showed extensive haemophagocytosis and ~7.4 % large lymphoma-like cells. On this basis PET-CT was suggested which showed enlarged spleen with diffuse uptake. BMBx showed nodular and intrasinusoidal collection of abnormal lymphoid cells. On immunohistochemistry, these cells were positive for CD20, CD5, MUM1, BCL-2, BCL-6 and negative for CD3, CD10 and CD23. CD34 highlighted focal intrasinusoidal pattern. The complete clinicopathological profile suggested the diagnosis of de novo CD5+ DLBCL, with primary hepatosplenic pattern of involvement. CD5+ DLBCL presenting as splenic infarct is very rare. This case was unusual as the diagnosis of a primary aggressive lymphoma with haemophagocytosis was established in a patient who presented with fever and splenic infarct without lymphadenopathy. This indicates the importance of good morphological assessment of a bone marrow aspirate and biopsy to make a correct diagnosis.
Literatur
1.
Zurück zum Zitat Yamaguchi Motoko, Seto Masao, Okamoto Masataka, Ichinohasama Ryo, Nakamura Naoya, Yoshino Tadashi et al (2002) De novo CD5 diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815–821CrossRefPubMed Yamaguchi Motoko, Seto Masao, Okamoto Masataka, Ichinohasama Ryo, Nakamura Naoya, Yoshino Tadashi et al (2002) De novo CD5 diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99:815–821CrossRefPubMed
2.
Zurück zum Zitat Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL (1996) CD5+ extranodal marginal zone B-cell (MALT) lymphoma: a low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 105:31–37CrossRefPubMed Ferry JA, Yang WI, Zukerberg LR, Wotherspoon AC, Arnold A, Harris NL (1996) CD5+ extranodal marginal zone B-cell (MALT) lymphoma: a low grade neoplasm with a propensity for bone marrow involvement and relapse. Am J Clin Pathol 105:31–37CrossRefPubMed
3.
Zurück zum Zitat Campo E, Swerdlow SH, Harris NL (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032CrossRefPubMedPubMedCentral Campo E, Swerdlow SH, Harris NL (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117:5019–5032CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Harada S, Suzuki R, Uehira K (1999) Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+ and CD5− with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13:1441–1447CrossRefPubMed Harada S, Suzuki R, Uehira K (1999) Molecular and immunological dissection of diffuse large B cell lymphoma: CD5+ and CD5− with CD10+ groups may constitute clinically relevant subtypes. Leukemia 13:1441–1447CrossRefPubMed
5.
Zurück zum Zitat Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S et al (2010) Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5- positive in comparison with CD-5 negative diffuse large B-cell lymphoma. Ann Oncol 21:2069–2074CrossRefPubMed Niitsu N, Okamoto M, Tamaru JI, Yoshino T, Nakamura N, Nakamura S et al (2010) Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5- positive in comparison with CD-5 negative diffuse large B-cell lymphoma. Ann Oncol 21:2069–2074CrossRefPubMed
6.
Zurück zum Zitat Dong HY, Gorczyca W, Liu Z, Tsang P, Wu CD, Cohen P et al (2003) B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol 119:218–230CrossRefPubMed Dong HY, Gorczyca W, Liu Z, Tsang P, Wu CD, Cohen P et al (2003) B-cell lymphomas with coexpression of CD5 and CD10. Am J Clin Pathol 119:218–230CrossRefPubMed
7.
Zurück zum Zitat Szyper-Kravitz M (2009) The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm. Isr Med Assoc J 11:633–634PubMed Szyper-Kravitz M (2009) The hemophagocytic syndrome/macrophage activation syndrome: a final common pathway of a cytokine storm. Isr Med Assoc J 11:633–634PubMed
9.
Zurück zum Zitat Shimazaki C, Inaba T, Okano A et al (2001) Clinical characteristics of B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS): comparison of CD5+ with CD5- B-LAHS. Intern Med 40:878–882CrossRefPubMed Shimazaki C, Inaba T, Okano A et al (2001) Clinical characteristics of B-cell lymphoma-associated hemophagocytic syndrome (B-LAHS): comparison of CD5+ with CD5- B-LAHS. Intern Med 40:878–882CrossRefPubMed
10.
Zurück zum Zitat Murase Takuhei, Yamaguchi Motoko, Suzuki Ritsuro, Okamoto Masataka, Sato Yumiko, Tamaru Jun-ichi et al (2007) Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109:478–485CrossRefPubMed Murase Takuhei, Yamaguchi Motoko, Suzuki Ritsuro, Okamoto Masataka, Sato Yumiko, Tamaru Jun-ichi et al (2007) Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5. Blood 109:478–485CrossRefPubMed
Metadaten
Titel
A Case Presenting with Splenic Infarct Diagnosed as Primary Bone Marrow CD5 Positive DLBCL: A Clinicopathological Correlation
verfasst von
Anupriya Bansal
Suchi Mittal
Jasmita Dass
Nitin Gupta
P. K. Agarwal
Jyoti Kotwal
Publikationsdatum
22.01.2016
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe Sonderheft 1/2016
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-016-0646-2

Weitere Artikel der Sonderheft 1/2016

Indian Journal of Hematology and Blood Transfusion 1/2016 Zur Ausgabe

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Medizinstudium Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.